Synthesis, stability, antiviral activity, and protease-bound structures of substrate-mimicking constrained macrocyclic inhibitors of HIV-1 protease

被引:58
作者
Tyndall, JDA
Reid, RC
Tyssen, DP
Jardine, DK
Todd, B
Passmore, M
March, DR
Pattenden, LK
Bergman, DA
Alewood, D
Hu, SH
Alewood, PF
Birch, CJ [1 ]
Martin, JL
Fairlie, DP
机构
[1] Univ Queensland, Ctr Drug Design & Dev, Brisbane, Qld 4072, Australia
[2] Victorian Infect Dis Ref Lab, Carlton, Vic 3053, Australia
[3] Royal Childrens Hosp, Sir Albert Sakzewski Virus Res Ctr, Herston, Qld 4029, Australia
关键词
D O I
10.1021/jm000013n
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Three new peptidomimetics (1-3) have been developed with highly stable and conformationally constrained macrocyclic components that replace tripeptide segments of protease substrates. Each compound inhibits both HIV-1 protease and viral replication (HIV-I, HIV-2) at nanomolar concentrations without cytotoxicity to uninfected cells below 10 mu M. Their activities against HIV-1 protease (K-i 1.7 nM (1), 0.6 nM (2), 0.3 nM (3)) are 1-2 orders of magnitude greater than their antiviral potencies against HIV-1-infected primary peripheral blood mononuclear cells (IC50 45 nM (1), 56 nM (2), 95 nM (3)) or HIV-1-infected MT2 cells (IC50 90 nM (1), 60 nM (2)), suggesting suboptimal cellular uptake. However their antiviral potencies are similar to those of indinavir and amprenavir under identical conditions. There were significant differences in their capacities to inhibit the replication of HIV-1 and HIV-2 in infected MT2 cells, 1 being ineffective against HIV-2 while 2 was equally effective against both virus types. Evidence is presented that 1 and 2 inhibit cleavage of the HIV-1 structural protein precursor Pr55(gag) to p24 in virions derived from chronically infected cells, consistent with inhibition of the viral protease in cells. Crystal structures refined to 1.75 Angstrom (1) and 1.85 Angstrom (2) for two of the macrocyclic inhibitors bound to HIV-1 protease establish structural mimicry of the tripeptides that the cycles were designed to imitate. Structural comparisons between protease-bound macrocyclic inhibitors, VX478 (amprenavir), and L-735,524 (indinavir) show that their common acyclic components share the same space in the active site of the enzyme and make identical interactions with enzyme residues. This substrate-mimicking minimalist approach to drug design could have benefits in the context of viral resistance, since mutations which induce inhibitor resistance may also be those which prevent substrate processing.
引用
收藏
页码:3495 / 3504
页数:10
相关论文
共 44 条
[11]   SETOR - HARDWARE-LIGHTED 3-DIMENSIONAL SOLID MODEL REPRESENTATIONS OF MACROMOLECULES [J].
EVANS, SV .
JOURNAL OF MOLECULAR GRAPHICS, 1993, 11 (02) :134-&
[12]  
EVANS SV, 1993, J MOL GRAPHICS, V11, P127
[13]   Conformational selection of inhibitors and substrates by proteolytic enzymes: Implications for drug design and polypeptide processing [J].
Fairlie, DP ;
Tyndall, JDA ;
Reid, RC ;
Wong, AK ;
Abbenante, G ;
Scanlon, MJ ;
March, DR ;
Bergman, DA ;
Chai, CLL ;
Burkett, BA .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (07) :1271-1281
[14]  
HAHN BH, 1994, TXB AIDS MED, P21
[15]   A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less [J].
Hammer, SM ;
Squires, KE ;
Hughes, MD ;
Grimes, JM ;
Demeter, LM ;
Currier, JS ;
Eron, JJ ;
Feinberg, JE ;
Balfour, HH ;
Dayton, LR ;
Chodakewitz, JA ;
Fischl, MA .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (11) :725-733
[16]   Errors in protein structures [J].
Hooft, RWW ;
Vriend, G ;
Sander, C ;
Abola, EE .
NATURE, 1996, 381 (6580) :272-272
[17]   IMPROVED METHODS FOR BUILDING PROTEIN MODELS IN ELECTRON-DENSITY MAPS AND THE LOCATION OF ERRORS IN THESE MODELS [J].
JONES, TA ;
ZOU, JY ;
COWAN, SW ;
KJELDGAARD, M .
ACTA CRYSTALLOGRAPHICA SECTION A, 1991, 47 :110-119
[18]  
Kempf DJ, 1996, CURR PHARM DESIGN, V2, P225
[19]   CRYSTAL-STRUCTURE OF HIV-1 PROTEASE IN COMPLEX WITH VX-478, A POTENT AND ORALLY BIOAVAILABLE INHIBITOR OF THE ENZYME [J].
KIM, EE ;
BAKER, CT ;
DWYER, MD ;
MURCKO, MA ;
RAO, BG ;
TUNG, RD ;
NAVIA, MA .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1995, 117 (03) :1181-1182
[20]   NOVEL BINDING MODE OF HIGHLY POTENT HIV-PROTEINASE INHIBITORS INCORPORATING THE (R)-HYDROXYETHYLAMINE ISOSTERE [J].
KROHN, A ;
REDSHAW, S ;
RITCHIE, JC ;
GRAVES, BJ ;
HATADA, MH .
JOURNAL OF MEDICINAL CHEMISTRY, 1991, 34 (11) :3340-3342